185 related articles for article (PubMed ID: 32675472)
1. Digital Quantification of Melanocytic Density in Resection Margins of Lentigo Maligna Using SOX10 Versus Hematoxylin-Eosin Staining.
Siarov J; Neittaanmäki N; Mölne J; Gillstedt M; Paoli J
Am J Dermatopathol; 2021 Apr; 43(4):273-277. PubMed ID: 32675472
[TBL] [Abstract][Full Text] [Related]
2. Staged Excision of Lentigo Maligna of the Head and Neck: Assessing Surgical Excision Margins With Melan A, SOX10, and PRAME Immunohistochemistry.
de Wet J; Plessis PJD; Schneider JW
Am J Dermatopathol; 2023 Feb; 45(2):107-112. PubMed ID: 36669074
[TBL] [Abstract][Full Text] [Related]
3. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna.
Gradecki SE; Valdes-Rodriguez R; Wick MR; Gru AA
Histopathology; 2021 Jun; 78(7):1000-1008. PubMed ID: 33280156
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
Lawrence CM; Rahim R; Charlton F; Husain A
Br J Dermatol; 2014 Aug; 171(2):298-303. PubMed ID: 24446749
[TBL] [Abstract][Full Text] [Related]
5. Margin control for lentigo maligna.
Robinson JK
J Am Acad Dermatol; 1994 Jul; 31(1):79-85. PubMed ID: 8021377
[TBL] [Abstract][Full Text] [Related]
6. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.
Magro CM; Yang SE; Zippin JH; Zembowicz A
Arch Pathol Lab Med; 2012 Dec; 136(12):1558-64. PubMed ID: 23194049
[TBL] [Abstract][Full Text] [Related]
7. Soluble adenylyl cyclase antibody (R21) as a diagnostic adjunct in the evaluation of lentigo maligna margins during slow Mohs surgery.
Solky AC; Zembowicz A
Am J Dermatopathol; 2014 Nov; 36(11):882-7. PubMed ID: 24698940
[TBL] [Abstract][Full Text] [Related]
8. Staged margin control techniques for surgical excision of lentigo maligna.
Raziano RM; Clark GS; Cherpelis BS; Sondak VK; Cruse CW; Fenske NA; Glass LF
G Ital Dermatol Venereol; 2009 Jun; 144(3):259-70. PubMed ID: 19528907
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna.
Bowen AR; Thacker BN; Goldgar DE; Bowen GM
Dermatol Surg; 2011 May; 37(5):657-63. PubMed ID: 21446989
[TBL] [Abstract][Full Text] [Related]
10. Lentigo maligna - anatomic location as a potential risk factor for recurrences after non-surgical treatment.
Greveling K; van der Klok T; van Doorn MB; Noordhoek Hegt V; Prens EP
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):450-454. PubMed ID: 27557425
[TBL] [Abstract][Full Text] [Related]
11. The impact of haematoxylin-eosin staining and immunohistochemistry of lentigo maligna and lentigo maligna melanoma margins on local recurrence.
Eckardt J; Behrens V; Kofler K; Forchhammer S; Häfner HM; Kofler L
Eur J Dermatol; 2022 Nov; 32(6):750-755. PubMed ID: 36856395
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study.
Florell SR; Boucher KM; Leachman SA; Azmi F; Harris RM; Malone JC; Martignoni G; Bowen GM; Gerwels JW; Hood AF
Arch Dermatol; 2003 May; 139(5):595-604. PubMed ID: 12756096
[TBL] [Abstract][Full Text] [Related]
13. Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study.
Ahlgrimm-Siess V; Massone C; Scope A; Fink-Puches R; Richtig E; Wolf IH; Koller S; Gerger A; Smolle J; Hofmann-Wellenhof R
Br J Dermatol; 2009 Dec; 161(6):1307-16. PubMed ID: 19566662
[TBL] [Abstract][Full Text] [Related]
14. A quantitative immunohistochemical evaluation of lentigo maligna and pigmented solar keratosis.
Lane H; O'Loughlin S; Powell F; Magee H; Dervan PA
Am J Clin Pathol; 1993 Dec; 100(6):681-5. PubMed ID: 8249917
[TBL] [Abstract][Full Text] [Related]
15. A model for lentigo maligna recurrence using melanocyte count as a predictive marker based upon logistic regression analysis of a blinded retrospective review.
Gorman M; Khan MA; Johnson PC; Hart A; Mathew B
J Plast Reconstr Aesthet Surg; 2014 Oct; 67(10):1322-32. PubMed ID: 24939827
[TBL] [Abstract][Full Text] [Related]
16. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines.
Agarwal-Antal N; Bowen GM; Gerwels JW
J Am Acad Dermatol; 2002 Nov; 47(5):743-8. PubMed ID: 12399768
[TBL] [Abstract][Full Text] [Related]
17. Lentigo maligna and malignant melanoma in situ, lentigo maligna type.
Flotte TJ; Mihm MC
Hum Pathol; 1999 May; 30(5):533-6. PubMed ID: 10333223
[TBL] [Abstract][Full Text] [Related]
18. The starburst giant cell is useful for distinguishing lentigo maligna from photodamaged skin.
Cohen LM
J Am Acad Dermatol; 1996 Dec; 35(6):962-8. PubMed ID: 8959956
[TBL] [Abstract][Full Text] [Related]
19. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin.
Muzumdar S; Argraves M; Kristjansson A; Ferenczi K; Dadras SS
J Cutan Pathol; 2018 Apr; 45(4):263-268. PubMed ID: 29377259
[TBL] [Abstract][Full Text] [Related]
20. Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features.
Star P; Rawson RV; Drummond M; Lo S; Scolyer RA; Guitera P
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1811-1820. PubMed ID: 33998703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
